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Abstract
Niemann-Pick Type C (NPC) is a progressive and life limiting autosomal recessive disorder caused by mutations in
either the NPC1 or NPC2 gene. Mutations in these genes are associated with abnormal endosomal-lysosomal
trafficking, resulting in the accumulation of multiple tissue specific lipids in the lysosomes. The clinical spectrum of
NPC disease ranges from a neonatal rapidly progressive fatal disorder to an adult-onset chronic neurodegenerative
disease. The age of onset of the first (beyond 3 months of life) neurological symptom may predict the severity of
the disease and determines life expectancy.
NPC has an estimated incidence of ~ 1: 100,000 and the rarity of the disease translate into misdiagnosis, delayed
diagnosis and barriers to good care. For these reasons, we have developed clinical guidelines that define standard
of care for NPC patients, foster shared care arrangements between expert centres and family physicians, and
empower patients. The information contained in these guidelines was obtained through a systematic review of
the literature and the experiences of the authors in their care of patients with NPC. We adopted the Appraisal
of Guidelines for Research & Evaluation (AGREE II) system as method of choice for the guideline development
process. We made a series of conclusive statements and scored them according to level of evidence, strengths of
recommendations and expert opinions. These guidelines can inform care providers, care funders, patients and their
carers of best practice of care for patients with NPC. In addition, these guidelines have identified gaps in the
knowledge that must be filled by future research. It is anticipated that the implementation of these guidelines will
lead to a step change in the quality of care for patients with NPC irrespective of their geographical location.
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Background
Niemann-Pick Type C (NPC) disease is a rare genetic
disease whose clinical spectrum ranges from a fatal ante-
natal disorder to an adult-onset chronic neurodegenera-
tive disease. The rarity of the disease and the scarcity of
expertise translate into misdiagnosis, delayed diagnosis
and barriers to adequate care. This results in additional
physical, psychological and intellectual impairments, in-
adequate or inappropriate treatment, loss of confidence
in the healthcare system, and patient disempowerment,
even though the diagnosis of NPC is compatible with
improved quality of life if a diagnosis is made promptly
and appropriate comprehensive management is insti-
tuted. There is as yet no disease-specific curative ther-
apy available, and the disease usually progresses to
premature death. The mainstay of management is
symptomatic supportive therapy using multidisciplinary
and multiprofessional teams of experts. Some countries
have national standard operating procedures to im-
prove the care of NPC patients, but the NPC commu-
nity, represented by the International Niemann-Pick
disease Alliance (INPDA), has not previously initiated
the development of a comprehensive disease management
guidelines to provide a resource for the multidisciplinary
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team, and to support patients and their primary profes-
sional caregivers on the current diagnosis, treatment,
monitoring and outcome measures for patients with NPC.
This document represents general guidelines, which in the
opinion of the authors can inform care providers about
the needs of patients with NPC in order to provide equit-
able and improved care, define standard of care for NPC
patients, foster shared care arrangements between expert
centres and family physicians, and empower patients. The
guidelines refer to the management of patients suspected
or diagnosed with NPC disease at any age. These guide-
lines should be of value to: a) specialist centres, other
hospital-based medical teams and other staff involved with
the care of NPC disease patients, b) family physicians and
other primary caregivers and c) patients and their families.
The guidelines have been developed by experts with ex-
tensive experience of European, Australian and North
American healthcare systems and populations. However,
they might equally be applicable to any country that
operates similar healthcare services. It is anticipated that
implementation of these guidelines will lead to a step
change in the quality of care for patients with NPC.
Methods
These guidelines have been developed by expert physi-
cians, geneticists, allied healthcare professionals and
patient support groups involved in the International
Niemann-Pick Disease Registry (INPDR) project (www.
inpdr.org),which is supported by the EU Directorate
General for Health and Consumers (DG-SANCO) via
the Consumers, Health, Agriculture and Food Executive
Agency (CHAFEA). The INPDR consortium comprises 27
partners from 13 countries in Europe, Australia, Canada
and the United States of America. One of the goals of the
INPDR is to support equitable care of Niemann-Pick
disease patients by standardizing the quality of care all
patients receive. In addition, the European Metabolic
Reference network (MetabERN) has adopted this guide-
line for the management of NPC patients within the
network.
The Guidelines Development Group (GDG) consisted
of expert representatives from a range of professional
groups including paediatric and adult neurologists,
paediatric and adult metabolic specialists, psychiatrists,
epidemiologists, clinical biochemists, geneticists, spe-
cialist metabolic dieticians, physiotherapists, psycholo-
gists, specialist nurses and patient support group
representatives. The GDG Committee agreed the remit
of the guidelines and selected a list of guidelines topics
for development.
A systematic literature review on NPC in the last
10 years until May 2017 was carried out using Medline,
MedLink, Embase and the Cochrane Library. Relevant pa-
pers, which were previously published were considered by
the GDG members as important were included. Searches
were limited to English language publications only. The
initial search identified 879 reference abstracts, of which
276 were accepted as relevant after the first screen.
References related to a single topic (i.e., Epidemiology,
Genetics, Pathophysiology, Clinical Diagnosis, Laboratory,
Imaging, Therapy, Recommendations) were pulled to-
gether and the GDG was divided into subgroups aimed to
critically appraise references devoted to a specific topic.
The committee met twice (June 2016, Birmingham, UK
and September 2016, Rome, Italy) and corresponded by
email on a regular basis throughout the duration of the
guideline development. During the first workshop, the
GDG adopted the second version of the Appraisal of
Guidelines for Research & Evaluation (AGREE II) system
as methodological reference in order to meet the guideline
development standards outlined in the AGREE II system:
howewer, our guideline didn’t partially or completely met
5/23 items outlined in the AGREE II system, and we
haven’t calculated quality scores for all appraisal items [1].
Relevant papers were evaluated by members of the
GDG before the evidence was considered. Section
leaders individually assessed the literature selected and
wrote a short document describing the study findings
and related recommendations. All GDG members dis-
cussed the draft documents. Evidence levels were classi-
fied in accordance with the Grading of Recommendations,
Assessment, Development and Evaluations (GRADE)
methodology and recommendations were graded from A
to C (Table 1). In addition, for the adoption of recommen-
dations, we structured a panel of experts that represented
group of specialists caring for NPC patients and used the
Delphi method for the development of our guidelines. In
total, 25 persons participated, and after the first round of
Delphi consensus two statements required substantial re-
vision and the expert opinion expressed in the guidelines
were based on the revised statements.
The guidelines will be published in an open access
journal and made freely accessible through the INPDR
and INPDA website. These guidelines will be revised
every 3–5 years to reflect new data pertaining to future
research findings, new therapies and the development of
diagnostic methods. The development of these guide-
lines was made without external financial support from
industries involved in the manufacturing of therapies for
NPC disease. Competing interests of members of the
guideline development group have been recorded in
writing and addressed. Developing treatment guidelines
in an objective and scientific manner for a rare disease
is challenging owing to the lack of randomized con-
trolled trials (RCT). We have attempted to apply all the
AGREE II domains in our guidelines development.
However, as the methodology was developed for com-
mon disorders, where there is wealth of evidence in a
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form of RCT, a large number of patients cared by large
number of clinical units, despite our best effort, we
found it difficult to apply AGREE II in full for an ultra-
rare disorder. The small number of patients available
for clinical studies, variability of the phenotype and
constraints on funding limit the opportunities to mount
clinical trials. We have therefore created guidelines using
the best available data, however imperfect it may be.
Defintion and epidemiology
Definition of NPC
Statement #1: NPC is a progressive and life limiting
autosomal recessive disorder caused by mutations in
either the NPC1 or NPC2 gene. Mutations in these genes
are associated with abnormal endosomal-lysosomal traf-
ficking, resulting in the accumulation of multiple lipids
in the lysosomes. Disease onset occurs through the life-
span, from antenatal life to maturity.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (94%), mostly agree
(6%), partially agree (0%), mostly disagree (0%) and
completely disagree (0%).
Niemann-Pick disease type C (OMIM#257220; OMIM
#607625) is a lysosomal storage disorder caused by muta-
tions in either NPC1 or NPC2 genes [2–4]. The two
genes code for their respective proteins, NPC1 and
NPC2 [5, 6]. The two proteins, working in a coordinated
manner, are believed to be involved in the cellular traf-
ficking of cholesterol [7] and other lipids in the late endo-
somal/post-lysosomal stage of lipid transport. Disease
causing mutations in either gene result in tissue accumu-
lation of multiple lipids (see Ref [8] for review). Both types
of NPC are inherited in an autosomal recessive manner.
NPC disease is a progressive disorder characterized by
neuro-visceral manifestations that can present at any age
from the perinatal period to maturity. Life expectancy in
patients with NPC disease varies with the age of onset
of the disease and ranges from a few days to several
decades [9–13].
How common is NPC disease?
Statement #2: NPC disease is rare, with an estimated
incidence of 1 case per 100,000 live births. The disease
is pan-ethnic, with at least 95% of all disease due to
mutations in the NPC1 gene and the remainder in the
NPC2 gene.
 Strength of recommendation: 2
 Level of evidence: C
 Experts opinion: completely agree (65%), mostly agree
(29%), partially agree (6%), mostly disagree (0%) and
completely disagree (0%).
Retrospective national expert centre based studies
from Australia, the Netherlands, the UK, Portugal,
Czech Republic, France and United Arab Emirates have
reported an annual incidence varying between 0.25 and
2.20 per 100,000 live births [11, 14–18]. Published inci-
dence data that includes information from prior to 1990
may underestimate the disease prevalence. These figures
should be compared with those recently compiled from
parallel large exome sequencing datasets [19]. In the lat-
ter study, when taking into account pathogenic muta-
tions, the incidence rate at conception of classical
clinical forms of NP-C was calculated to 1.12 per
100,000 (1/89,229). In addition, owing to better aware-
ness and improved diagnostic methods, a significantly
higher proportion of adult-onset cases have been diag-
nosed during the past 5 years [20], therefore a recalcu-
lation would likely approach a figure slightly higher than
Table 1 Evidence levels and strength of recommendations
Item Definition
Level of evidence
A. High-quality evidence Further research is unlikely to
change our confidence in the
estimate of effect. Consistent
evidence from the RCTs without
important limitations or
exceptionally strong evidence
from observational studies.
B. Moderate-quality evidence Further research is likely to have
an important impact on our
confidence in the estimate of
effect and may change the
estimate. Evidence from RCTs
with important limitations
(inconsistent results,
methodologic flaws, indirect or
imprecise), or very strong
evidence from observational
studies.
C. Low-quality evidence Further research is very likely to
have an important impact on our
confidence in the estimate of
effect and is likely to change the
estimate. Evidence for at least
one critical outcome from
observational studies, case series,
or from RCTs with serious flaws,
or indirect evidence, or expert’s
consensus.
Strength of recommendation
1. Strong recommendation Recommendation can apply to
most patients in most
circumstances.
2. Weak recommendation The best course of action may
differ depending on
circumstances or patient or
society values. Other alternatives
may be equally reasonable.
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1/100,000. Interestingly, in the Wassif et al. study, the
inclusion of two variants of controversial pathogenicity
would suggest a much higher incidence in the range of
1/40,000 of still unrecognized late onset, milder form
[19]. Indeed, attenuated phenotypes may not be sus-
pected clinically, or may be missed by the diagnostic
laboratories.
Clinical presentation
How best can NPC disease be classified?
Statement #3: The clinical manifestations and life ex-
pectancy of NPC patients vary markedly with age of on-
set of the disease. In neonates and children, NPC may
initially present as a systemic disease with subtle neuro-
logical manifestations, but for practical purposes, NPC is
best classified according to the age of onset of neuro-
logical manifestations as follow:
1. visceral-neurodegenerative form
 Early-infantile (< 2 years)
2. neurodegenerative form
 Late-infantile (2–6 years)
 Juvenile (6–15 years)
3. Psychiatric-neurodegenerative form
 Adult (> 15 years)
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (50%), mostly agree
(38%), partially agree (13%), mostly disagree (0%)
and completely disagree (0%).
The clinical spectrum of NPC disease ranges from a
neonatal rapidly progressive fatal disorder to an adult-
onset chronic neurodegenerative disease. Based on data
gathered from a large cohort of French NPC patients,
the age of onset of neurological symptoms predicts the
severity of the disease and determines life expectancy
[11]. Disease classifications based on the age of onset
of the first (beyond 3 months of life) neurological
symptom may be used to guide clinicians in providing
day to day care, genetic counselling and estimate the
trajectory of the disease course. There is an overlap be-
tween the neurological forms, as NPC disease com-
prises a continuum [20]. Relative distributions of the
five age categories based on the national/international
registry are listed in Table 2. In addition, atypical pre-
sentations such as: a) the fatal systemic perinatal form
(foetal hydrops or early liver, multi-organ or respira-
tory failure) and b) initial systemic disease only (in in-
fants and children with a variable latency before onset
of neurological manifestations) constitutes a small, but
significant, proportion of cases. The global contribu-
tion of these forms has rarely been calculated, and
such patients are typically not enrolled in registries.
Two features emerge from the compiled data pre-
sented in Table 2: the early infantile neurological onset
form appears more frequent in Southern Europe, and
2) patients with an adolescent/adult onset neurological
form seem to represent at least 20% of the cases of
NPC and, owing to their longer survival, probably con-
stitute the largest patient group in terms of disease
prevalence [20].
Is the clinical presentation different in specific age
groups?
Pre/perinatal (< 2 months)
Statement # 4: NPC manifests in the pre/perinatal age
group primarily as liver disease presenting with pro-
longed cholestatic jaundice, hepatosplenomegaly and
in some cases acute liver failure, with or without
pulmonary disease.
Table 2 Distribution of clinical forms of NP-C disease in large cohorts
Neonatal systemic
fatal (%)
Early infantile
neurological
onset (%)
Late infantile
neurological
onset (%)
Juvenile
neurological
onset (%)
Adolescent/adult
neurological
onset (%)
Total no.
Early studies
France+ European countries [70] 12 30 23 30 5 125
Spain [71–73] 7 37 21 25 11 57
Italy [74, 75] 7 26 32 23 12 43
France [11] 9 26 22 26 16 107
Recent studies
Germany [22] 3 3 35 54 5 37
Czech Republic [12] 6 17 24 37 17 54
UK [13] 5 6 39 32 19 132
European countries [20] – 11 31 31 27 145
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 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (60%), mostly agree
(40%), partially agree (0%), mostly disagree (0%) and
completely disagree (0%).
NPC disease presentation during the neonatal period
varies from subject to subject, with the commonest pres-
entation being prolonged jaundice and mild hepatosple-
nomegaly. In the majority of cases, jaundice resolves
spontaneously by 3–4 months of age, while organome-
galy persists to a variable degree. Neurological symptoms
develop later, with a delay varying between a couple of
months and the childhood period, or even later in a few
cases. However, in about 8–9% of the cases, the hepatic
manifestations may progress rapidly to acute liver and/or
multi-organ failure and subsequently lead to death within
6 months. In some circumstances, the initial presentation
may be foetal ascites/hydrops. The rapidly progressing co-
hort may have associated neurological presentations such
as failure to thrive and hypotonia [10].
Early infantile (2 months to < 2 years):
Statement #5: Hypotonia and delay in developmental
motor milestones characterize the neurological manifest-
ation of NPC in early infancy. Hepatosplenomegaly and/
or a neonatal prolonged jaundice are almost invariably
noted.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (53%), mostly agree
(40%), partially agree (7%), mostly disagree (0%) and
completely disagree (0%).
Hypotonia may be due to cerebral and/or peripheral
nerve pathology in these early infantile forms. In the
latter case, distal motor limb deficit may be clinically ob-
vious. Communication is initially well preserved. Vertical
supranuclear gaze palsy (VSGP) may be present, but is
difficult to recognize.
Late infantile (2 to < 6 years)
Statement #6: Clumsiness, gait disturbance and fine
motor skill impairments characterize this age of onset of
the disease. Speech delay, a history of neonatal cholesta-
sis and variable visceromegaly may be noted. VSGP is
typically present, but is often unrecognized. The first
symptoms may be gelastic cataplexy (sometimes associated
with narcolepsy) or sensory deafness. Epilepsy is quite
frequent in subsequent evolution in this group.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (67%), mostly agree
(33%), partially agree (0%), mostly disagree (0%) and
completely disagree (0%).
Juvenile (6 to 15 years)
Statement #7: Juvenile-onset is the 2nd most frequent
presentation of NPC and manifests as cognitive impair-
ment (lagging behind peers in school, language and
learning difficulties), coordination problems (clumsiness,
frequent falls, progressive ataxia and dystonia) and
VSGP.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (60%), mostly agree
(40%), partially agree (0%), mostly disagree (0%) and
completely disagree (0%).
Adult (> 15 years)
Statement #8: Adolescent and adult-onset NPC patients
may represent up to a third of all NPC patients. Cogni-
tive impairment invariably occurs and tends to present
with higher rates of psychiatric illness co-existing with
neurological manifestations. Diagnostic delay is common,
but is minimised if the characteristic VSGP is identified.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (27%), mostly agree
(67%), partially agree (7%), mostly disagree (0%) and
completely disagree (0%).
The age of onset of NPC varies significantly across the
lifespan (Table 3) [11], although increasingly patients are
recognized as presenting with late-onset illness in ado-
lescence, early and mid-adulthood and may present as
late as the 7th decade [21]. Early development is often
completely normal achieving all developmental mile-
stones appropriate to their age. In a large international
prospective registry, the adolescent and adult-onset form
occurred in 27% of all NPC patients [20]. Patients in this
age group are less likely to present with seizures, gelastic
cataplexy and diagnosed visceral disease. Typical presen-
tation is a history of progressive ataxia/dystonia, and/or
cognitive decline, and/or atypical psychotic symptoms,
often associated to vertical gaze palsy at clinical examin-
ation [11, 22–25]. Other reported symptoms dysarthria
and dysphagia are also very frequent but occur later.
Some patients may have previous symptoms that have
begun several years before onset of the chronic neurode-
generative disease such as undiagnosed hepatomegaly or
splenomegaly with spontaneous remission in childhood,
learning disorder in childhood, and hearing defect. In
late-onset patients, diagnostic delay is common and is
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often 5 years or more, although this delay may be mini-
mised when the more specific symptom of VSGP is
recognised [26]. Despite the diagnostic utility of VSGP, it
may not be present if patients are examined early in the
course of the disease, and its absence should not rule
out the diagnosis of NPC.
Pre-senile cognitive impairment, prominently affecting
memory and executive function, invariably occurs in
adolescent and adult-onset NPC patients [23, 26–28].
Furthermore, up to one third of adolescent and adult pa-
tients may present with psychiatric symptoms such as
psychosis (paranoid delusions, auditory and/or visual
hallucination) and depression which predate neuro-
logical manifestations and exhibit atypical features, in-
cluding treatment- resistance [12, 26, 29, 30]. Up to one
third of patients presenting with psychiatric illness, most
commonly psychosis, may show a poor response to
treatment. The combination of psychiatric and neuro-
logical presentation should raise the clinical suspicion of
a diagnosis of NPC.
The NPC-suspicion index assists in the diagnosis of
adult patients with NPC, with strong indicators in-
cluding cognitive and psychotic symptoms, and the
combination of neurological with psychiatric signs is
Table 3 Summary of Clinical signs and symptoms in NP-C, by age of onset
Age at onset Systemic manifestations Neurological/psychiatric manifestations
Pre−/peri-natal (< 2 months) Foetal ascites/hydrops Hypotonia
Hepatosplenomegaly
Cholestatic jaundice
Thrombocytopenia
Pulmonary disease
Liver failure
Failure to thrive
Early-infantile (2 m to < 2 yrs.) Hepatosplenomegaly or Splenomegaly
(isolated or with neurological manifestations)
Central hypotonia
Delayed developmental motor milestones,
speech delay
Prolonged neonatal jaundice Dysphagia, spasticity
VSGP
Late-infantile (2 to < 6 yrs.) Hepatosplenomegaly or Splenomegaly
(isolated or with neurological manifestations)
Developmental delay/regression, speech delay
History of prolonged neonatal
cholestatic jaundice
Clumsiness, Frequent falls,
Progressive ataxia, dystonia, dysarthria,
dysphagia,
Seizures (partial/generalized)
Cataplexy
VSGP
Hearing loss
Juvenile (6 to 15 yrs.) Hepatosplenomegaly or Splenomegaly (isolated or
with neurological manifestations; often not present)
Poor school performance, learning disability.
Loss of language skill
Frequent falls, clumsiness
Progressive ataxia, dysarthria, dystonia,
dysmetria, dyskinesia, dysphagia
VSGP
Gelastic cataplexy
Seizures
Behavioural problems
Adolescent/adult (> 15 yrs.) Splenomegaly (often not present; isolated in
very rare cases)
Cognitive decline, dementia, learning
disability
Psychiatric signs: Schizophrenia (psychosis),
depression.
Clumsiness, progressive motor symptoms,
tremor, ataxia, dystonia/dyskinesia, dysarthria,
dysphagia
VSGP
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highly suggestive of NPC [26, 31]. NPC patients may
have initially a poorly specific presentation, but with
accumulation of typical disorders, probability of diag-
nosis strongly increases, as illustrated by the series of
ataxia clinic patients with recessive disease and cogni-
tive decline for whom NPC was genetically confirmed
in one sixth of them [25].
Conditions raising the suspicion of NPC and differential
diagnosis
The symptoms and signs of NPC vary with age at
disease onset. There are numerous conditions raising
the suspicion of NPC and other age appropriate diseases
should also be excluded.
Statement #9: In the first 2 years of life, history of pro-
longed neonatal jaundice, hepatosplenomegaly and/or
developmental delay should raise the possibility of NPC.
The differential diagnosis includes other causes of chole-
static jaundice, idiopathic neonatal hepatitis, Wolman
disease, Niemann-Pick type A/B, Gaucher type III disease
and Cerebrotendinous xanthomatosis with or without
initial developmental delay.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (50%), mostly
agree (36%), partially agree (14%), mostly disagree
(0%) and completely disagree (0%).
Statement #10: From childhood to adolescence, neuro-
logical disease manifestations can be subtle, ranging from
clumsiness and poor school performance to progressive
ataxia, dysarthria and dystonia. Other age appropriate
neurodegenerative disorders must be ruled out.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (73%), mostly agree
(27%), partially agree (0%), mostly disagree (0%) and
completely disagree (0%)
NPC can also manifest as isolated splenomegaly or
hepatosplenomegaly and mimics NPB disease (same
storage cells) or Gaucher disease. NPC should be
considered in differential diagnosis in patients with
unexplained isolated splenomegaly with or without
hepatomegaly at any age.
Statement #11: Adult patients presenting with an
atypical psychotic disorder or a progressive neurological
syndrome including ataxia, dystonia, cognitive difficul-
ties, dysarthria, or VSGP with or without splenomegaly
should be tested for NPC. Other neurodegenerative disor-
ders such as Huntington disease, Wilson disease, Cerebro-
tendinous xanthomatosis, GM1 or GM2 gangliosidoses
and Friedreich Ataxia which mimic NPC must be ruled
out. However, on the contrary to several of those diseases,
in NPC patients, there is no peripheral neuropathy and
brain MRI is normal or shows nonspecific abnormalities
(mainly atrophy).
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (67%), mostly agree
(33%), partially agree (0%), mostly disagree (0%) and
completely disagree (0%).
NPC disease severity score
Statements #12: NPC-specific disease severity scores are
useful adjuncts to clinical judgement in assessing disease
burden, response to therapy and determining prognosis.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (53%), mostly agree
(40%), partially agree (7%), mostly disagree (0%) and
completely disagree (0%).
Clinical assessment of disease severity is dependent on
the experience of the treating clinician, but such clinical
judgement may not be reliable when the disease is rare
and most clinicians have limited exposure to the condi-
tion. Three severity scoring systems and predictive
models have been developed in an attempt to help the
clinician accurately assess disease burden and monitor
progression in time or stabilisation with therapy and es-
timate prognosis at an early stage [22, 24, 32]. These
NPC–specific scales were based on neurological impair-
ments that allow a calculation of a composite score to
assess disease severity. Bearing in mind the resources
available to most physicians in practice, we suggest
the use of a modified version (Table 4) of the widely
implemented and user-friendly model [24] though it
has not been formally validated for treatment monitor-
ing. No predictive model allows the unequivocal cat-
egorisation of patients into definite groups and
predictive models are best viewed as useful adjuncts to
clinical judgement. Regular reassessment of severity
over the course of the disease is mandatory to assess
the response to treatment.
Is saccadic eye movement evaluation a measure of disease
status?
Statements #13: Measures of horizontal saccadic func-
tion are robust objective measures of illness status and
correlate with indices of brain structure.
 Strength of recommendation: 2
 Level of evidence: B
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 Experts opinion: completely agree (23%), mostly
agree (23%), partially agree (46%), mostly disagree
(8%) and completely disagree (0%).
Vertical saccadic gaze palsy is a clinical hallmark of
the disease, whereas horizontal saccadic gaze deterio-
rates less rapidly and is a useful objective biomarker of
disease severity illness. Horizontal saccadic gain, which
correlates strongly with measures of pontine area and
parietal eye field volume as measured on MRI, and self-
paced saccades, an index of frontal eye field integrity,
may be the most robust measure in adults [33, 34].
Investigations
Once NPC is suspected clinically, diagnosis can be con-
firmed by the combination of biochemical and molecular
genetic studies [35]. In recent years, several plasma me-
tabolites (cholestane-3β, 5α, 6β-triol, lyso-sphingomyelin
isoforms and bile acid metabolites) have emerged as sen-
sitive and specific diagnostic biomarkers for NPC and
their study, completed by genetic analyses, should now
be considered as the first line laboratory testing [35, 36].
The filipin test, although still very useful, is no longer
considered as the primary tool. Figure 1 describes a re-
vised laboratory diagnostic algorithm for NPC.
What investigations should be performed in individual
suspected with NPC?
Biomarkers
Statements #14: Assessment of biomarkers should be
considered as a first-line test to screen for NPC. Three
classes of biochemical markers are either currently in use
(oxysterols; lyso-SM-509 and lyso-sphingomyelin) or
are in development (bile acid derivatives).They can be
used alone or in combination to enhance sensitivity
and specificity. The diagnosis, however, must in all
cases be confirmed by mutation analysis and if neces-
sary, filipin test.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (75%), mostly agree
(13%), partially agree (13%), mostly disagree (0%)
and completely disagree (0%).
Table 4 Clinical Severity assessment
I. Functional disability scale (Modified from Pineda et al. [24])
Ambulation Score
Normal 0
Clumsiness 1
Autonomous ataxic gait 2
Outdoor assisted ambulation 3
Indoor assisted ambulation 4
Wheelchair-bound 5
Manipulation Score
Normal 0
Tremor 1
Slight dysmetria/dystonia (allows autonomous
manipulation)
2
Mild dysmetria/dystonia (requires help for
several tasks but is able to feed themselves)
3
Severe dysmetria/dystonia (requires assistance
in all activities)
4
Language Score
Normal 0
Delayed acquisition 1
Mild dysarthria (understandable) 2
Severe dysarthria (only comprehensible to
some family members)
3
Non-verbal communication 4
Absence of communication 5
Swallowing Score
Normal 0
Occasional dysphagia 1
Daily dysphagia 2
Nasogastric tube or gastric button feeding 3
Eye movements Score
Normal 0
Slow ocular pursuit 1
Vertical ophthalmoplegia 2
Complete ophthalmoplegia 3
Seizure Score
No 0
Yes, controlled by antiepileptic drugs 2
Yes, uncontrolled on two or more
antiepileptic drugs of maximally tolerable dose
4
II. Neurocognitive Assessment
Development (< 12 years old):
O Normal
O Mild learning delay
O Moderate learning delay
O Severe delay/plateau
O Regression
Table 4 Clinical Severity assessment (Continued)
Memory (> 12 years old):
O Normal
O Mild impairment
O Moderate
O Difficult following commands
O Unable to follow commands
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Oxysterols (cholesterol oxidation products)
The oxysterols cholestane-3β, 5α, 6β-triol (C-triol) and
7-ketocholesterol (7-KC), are well established and ac-
cessible to clinicians (implemented in > 30 clinical la-
boratories worldwide). Both are sensitive markers of NP-
C, though C-triol is more specific [37, 38].
Potential limitations:
– Elevated values have been reported in other metabolic
disorders, particularly acid sphingomyelinase
deficiency and lysosomal acid lipase deficiency, and
to a lesser degree Cerebrotendinous xanthomatosis
and Smith Lemli Opitz syndrome. These false positive
results may reflect artefacts of the derivatization
process used in the assay.
– Spurious values in the setting of neonatal cholestasis
may result from assay interference. In this clinical
setting, plasma bile acids are test of choice
(see below).
– Overlap between upper quartile of NPC1 carriers
and NPC1 patients must be considered when
screening populations with low carrier frequency
(e.g., general population).
Lyso-sphingolipids
The simultaneous mass spectrometric measurement in
plasma of lyso-sphingomyelin (lyso-SM) (also known as
sphingosyl-phosphorylcholine) [39] and of an analogue
of unclear structure named lyso-sphingomyelin 509
(lyso-SM 509) appears as a very promising tool for initial
screening of patients with either NPC or acid sphingo-
myelinase deficiency (ASMD) [39–44]. Striking elevations
of Lyso-SM 509 have been reported in both NPC and
ASMD, with high sensitivity for detecting both disorders,
but poor distinction between them. For lyso-SM, a large
increase only occurs in ASMD, with marginal or no eleva-
tion in NPC. Therefore, the combined assay of lyso-SM
509 and lyso-SM provides a good discrimination between
Fig. 1 Niemann-Pick disease type C laboratory diagnosis algorithm. Modified from: Patterson et al. [36, 47]. Abbreviations: GD: Gaucher disease;
ASMD: acid sphingomyelinase deficiency; EM: electron microscopy; VUS: variant of unknown significance; MLPA: Multiplex Ligation-dependent
Probe Amplification (evaluates copy number changes, allows detection of large deletions or false homozygous status with a deletion on the
other allele); lysoSM: lysosphingomyelin. aElevated cholestane-triol or bile acid derivative and/or lysoSM-509, with normal or slightly elevated
lysoSM. bCholestane-triol also elevated in ASMD, acid lipase deficiency, cerebrotendinous xanthomatosis, certain neonatal cholestasis conditions.
All lysoSM analogues and bile acid derivative are elevated in ASMD. cI-cell disease (ML-II and -III) gives a false positive result (very different clinical
features). dASMD can give a similar filipin pattern. eCheck allele segregation by parental study or other test
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NPC and ASMD. A high lysoSM-509/lysoSM ratio
appears very specific of NPC. Further simultaneous
measurement of other lysosphingolipids (e.g. glucosyl-
sphingosine) in the same analysis can also discriminate
other sphingolipidoses of clinical relevance – particularly
Gaucher disease [42, 44].
Potential limitations:
– The structure of lyso-SM-509 is unknown, and exact
concentrations cannot be measured
– Experience of clinical laboratories with Lyso-SM-509
and lyso-SM is still limited.
– Specificity of lyso-SM-509 among sphingolipidoses
other than NPC and ASMD appears good [42–44]
but will require further studies.
– It is still unclear whether this biomarker can
discriminate between NPC1 carriers and NPC1
patients, which has implications for population
screening.
Bile acids
Several unusual bile acid species in plasma and urine
have been identified in NPC. The most important
analytical species is 3β, 5α, 6β-trihydroxy-cholanoyl-
glycine, detectable in plasma and dried blood spots
[45, 46].
Potential benefits:
– It is highly sensitive and more specific than
oxysterols (only elevated in acid sphingomyelinase
deficiency and NPC).
– From available data, it provides complete
discrimination between NPC1 carriers and NPC1
patients, suggesting it may be a biomarker of choice
for population screening.
– It does not require derivatization and is less prone
to interferences in the context of neonatal
cholestasis, suggesting it may be the test of choice
for diagnosing NPC disease in this clinical subset.
– This biomarker has greater stability than C-triol and
can be shipped to diagnostic laboratories at ambient
temperature.
Potential limitations:
– Test is new and performed at present in only a
couple of research institutions.
– The biomarker has not been validated prospectively
in clinical laboratories.
Good correlation has been observed between levels of
the 3 biomarkers cholestane-triol, trihydroxycholanoyl-
glycine and lyso-SM-509 in the same patient, but, from
limited data, not necessarily with the level of lysosomal
cholesterol storage observed in the filipin test.
Molecular genetic studies:
Statements #15: Any individual in whom the diagnosis
of NPC is considered based on their clinical manifestation
and/or abnormal biomarker profile should undergo genetic
testing for NPC genes to confirm the diagnosis. Referral to
a clinical geneticist or genetic counsellor should be
considered upon the diagnosis of NPC.
 Strength of recommendation: 1
 Level of evidence: A
 Experts opinion: completely agree (81%), mostly agree
(19%), partially agree (0%), mostly disagree (0%) and
completely disagree (0%).
Mutation analysis of NPC1 and NPC2 genes is
mandatory to confirm the diagnosis of NPC. In addition,
it is the only reliable method to diagnose NPC carriers
within the family and the highly preferred strategy for
prenatal diagnosis. Furthermore, it may be useful to es-
tablish genotype-phenotype correlations. However, some
genetic changes (e.g. deep intronic mutations, large
deletions/ duplications) may not be identified by routine
sequencing methods and will require complementary
testing [47]. Nonetheless, a small proportion of mu-
tated NPC1 alleles have remained unidentified in
proven patients. The segregation of the alleles should
be confirmed in parents. The identification of two al-
leles with known disease-causing mutations in either
NPC1 or NPC2 gene confirms the diagnosis of NPC.
To date, about 700 NPC1variants have been reported,
among which around 420 are considered as patho-
genic, with only a limited number of common
(p.I1061T, p.P1007A) or recurrent (often in certain
populations) mutations. Thus, the interpretation of
new missense and splicing mutations should be
undertaken with caution and their pathogenic nature
must be verified.
Although genotype/phenotype correlations are difficult
to establish, some conclusions can be drawn from current
evidence:
The presence in both alleles of a very severe muta-
tion (frameshift, nonsense, large deletion) usually re-
sults in early-infantile neurological disease (with also a
higher risk of severe – possibly fatal – neonatal sys-
temic disease). From observations in homozygous
patients, an increasing number of recurrent NPC1 mis-
sense mutations (e.g. p.G1240R) can also be classified
in this category.
The p.I1061T NPC1 mutation [48, 49] has been re-
ported in a large number of individuals; in homozy-
gosity, it has mostly been associated with a juvenile
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neurological onset, less frequently with a late infantile
neurological phenotype. In heterozygosity, depending
on the second mutation, it is also often found in pa-
tients with an adolescent/adult onset form [13].
The p.P1007A NPC1 mutation appears more com-
monly associated with a juvenile or adult onset form
than with a late infantile one [22, 50]. Patients carrying
this mutation (even on one allele) have been difficult to
diagnose using the filipin test, as p.P1007A is the proto-
type of NPC1 mutations associated with a less severe
block in cholesterol egress from lysosomes, resulting in
the so-called “variant” filipin phenotype [50].
Lately, an increasing number of recurrent NPC1 mis-
sense mutations associated with a late-onset neurological
form (e.g. p.R978C, p.G992R, p.D874V), have been re-
ported even when found in compound heterozygosity
with a severe or null allele.
Thus far, 26 pathogenic NPC2 mutations have been
described. Most are frameshift or nonsense as well as a
large deletion variants leading to a severe clinical pheno-
type. Among the reported missense mutations, two vari-
ants (p.V39 M and p.P120S) have been associated with
the juvenile or adult forms of the disease. More patients
originating from North Africa, Italy and Turkey have
been described with NPC2 mutations.
Finally, studies of numerous multiplex families have
indicated that mutations (either NPC1 or NPC2) appear
largely predictive of the neurological course, and not of
the systemic disease.
The Filipin test
What is the diagnostic role of the filipin test in the
era of new biomarkers?
Statements #16: Filipin test is no longer considered a
first line test for the diagnosis of NPC. It still remains an
extremely useful diagnostic tool in uncertain cases in
which biomarkers and/or molecular analysis present in-
conclusive results and to assess the pathogenicity of novel
genetic variants.
 Strength of recommendation: 1
 Level of evidence: A
 Experts opinion: completely agree (81%), mostly agree
(19%), partially agree (0%), mostly disagree (0%) and
completely disagree (0%).
Until recently, the demonstration of unesterified choles-
terol accumulation within the lysosomes by filipin testing
was considered to be the gold standard test for the diag-
nosis of NPC disease [11, 47, 51]. Since this assay needs to
be performed on cultured fibroblasts obtained from skin
biopsies, it is invasive and has a long turnaround time.
Additionally, the assay is technically challenging, labour
intensive and is performed only in specialized laboratories
[51]. Due to these drawbacks, and in the light of the re-
cent discovery of several sensitive and specific blood
biomarkers, filipin staining is no longer considered as a
first line test for the diagnosis of NPC [35]. However, it
is very useful to assess the pathogenicity of novel gen-
etic variants. It also remains a useful diagnostic tool in
uncertain cases in which biomarkers and/or molecular
analysis present inconclusive results. In particular, it is
important to keep in mind that to date all biomarkers,
except bile acids which have not yet been fully vali-
dated, do not completely differentiate between hetero-
zygous and affected patients [39, 52, 53]. In these cases,
if only one pathogenic mutation is found by molecular
analysis of NPC1 and NPC2, filipin testing should be
performed. In some cases, distinction between a “vari-
ant” filipin profile and the slightly abnormal filipin pro-
file observed in a number of NPC heterozygotes may
however be difficult. Consequently, in a few patients, it
may not be possible to definitively conclude in spite of
comprehensive investigations.
Brain imaging
What is the role of brain imaging in the diagnosis
and follow-up of NPC?
Statements #17: Brain imaging changes in individuals
with NPC are variable and non-specific, but the most
commonly reported changes are reductions in volume of
the cerebellum, hippocampus, and subcortical grey
matter, in addition to subtle changes in most white
matter regions.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (47%), mostly agree
(53%), partially agree (0%), mostly disagree (0%) and
completely disagree (0%).
Neuroimaging data gathered primarily from adoles-
cent and adult individuals with NPC show a variable
pattern, with some being normal, particularly early in
the course of the illness, while most patients will dem-
onstrate cerebellar volume changes, which correlate
with measures of ataxia and ocular-motor function
[54]. Reductions in the volume of the hippocampus,
basal ganglia and thalamus are also associated with
progressive illness [55]. White matter disease is often
widespread, most detectable as changes on diffusion
imaging [56] or visually as atrophy of the corpus callo-
sum [57]. Increased pontine to mid-brain ratio, much
like that seen in progressive supranuclear palsy, is seen,
albeit to a lesser degree [58]. In some patients, brain at-
rophy may predominantly affect frontal and temporal
regions [59]. However, these changes are often subtle
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and non-specific, and may be more useful as illness bio-
marker than as a diagnostic tool.
Managment
NPC disease is not yet curable but is an eminently treat-
able condition. Optimal disease management employs a
multi-disciplinary, multi-professional team based in a
specialist centre, closely liaising with community care
providers (Table 5). The mainstay of therapy is symptom
management employing disease modifying agent(s) when
available.
Statements #18: Patients with NPC exhibit multisys-
tem disease manifestations and benefit from multidis-
ciplinary follow up from physicians and allied health
care professionals with experience in this condition.
Wherever possible, patients identified with NPC
should be referred to a centre with expertise in the
care of this condition.
 Strength of recommendation: 1
 Level of evidence: A
 Experts opinion: completely agree (100%), mostly
agree (0%), partially agree (0%), mostly disagree (0%)
and completely disagree (0%).
Symptomatic therapy
What symptomatic therapy should be considered for
a patient with NPC disease?
The following functional assessments should take
place at the time of diagnosis or symptom onset and at
regular intervals thereafter for optimal symptom control
and functional capacity (Table 6).
Growth and developmental delay
Statements #19: The growth of children with NPC
(height, weight and head circumference) should be
assessed at regular intervals as part of routine health
assessments by their primary health care provider. In
addition, their developmental progress should be monitored
using age appropriate instruments.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (80%), mostly agree
(20%), partially agree (0%), mostly disagree (0%) and
completely disagree (0%).
Mobility
Statements #20: Mobility, balance, core stability, trunk
control, spasticity, foot posture and strength should be
Table 5 Multidisciplinary assessments of patients with NPC
Discipline Features of NPC for which this discipline may be of assistance Reference
Primary care physician Assist with general medical care; coordinate specialists;
provide support for family
Expert opinion
Metabolic diseases specialist Diagnosis of NPC and exclusion of other disorders in the
differential diagnosis; ongoing patient assessment for
disease progression and response to therapy
[47]
Neurologist Cataplexy, movement disorders, dystonia, and seizures [60]
Psychiatrist Psychosis, behavioural disturbances, depression [26]
Neuro-ophthalmologist Diagnosis (vertical gaze palsy) and assess response to therapy
(changes in saccadic eye movement velocity)
[61]
Anaesthesiologist Assess for anaesthetic risk as needed [76, 77]
Neuropsychologist Assess for cognitive involvement at baseline and in
response to therapy
[63]
Speech and language therapist Assess for dysphagia and aspiration risk; speech
therapy for children
Expert opinion
Occupational and physical
therapists/Rehabilitation physician
Assess development and develop aids and home
adjustments as needed for patients with communication
and physical challenges
[64]
Orthopaedic surgeon Assess the need for surgical correction of severe scoliosis,
osteo-articular retractions, spasticity treatments and
hip problems.
Expert opinion
Nutritionist/Gastroenterologists Assess nutritional status in patients who may be losing
weight due to dysphagia or side effects of therapy;
Gastrostomy tube insertion when swallowing is unsafe.
[65]
Social worker Support of patients and families living with disabilities
who require enhanced resources in the community
Expert opinion
Genetic counsellor Provide counselling for families as to recurrence risk
and options for prenatal diagnosis if desired
[47]
Geberhiwot et al. Orphanet Journal of Rare Diseases  (2018) 13:50 Page 12 of 19
assessed regularly by a suitably qualified physical ther-
apist. Strategies to maintain optimal mobility and reduce
falls such as providing an appropriate walking/mobility
aids, ankle-foot orthotics and exercise programs should
be sought proactively. A structured and personalized re-
habilitation program may prolong mobility and transfer
ability.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (67%), mostly agree
(33%), partially agree (0%), mostly disagree (0%) and
completely disagree (0%).
Swallowing and diet
Statements #21: NPC patients should undergo a com-
prehensive swallowing assessment by a speech and lan-
guage therapist and nutritional review by a dietician.
Instruction in dietary modification and compensatory
postures may be beneficial for individuals with dyspha-
gia. The family should be educated regarding the likely
eventual need for assisted feeding, as part of an ongoing
process.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (86%), mostly agree
(14%), partially agree (0%), mostly disagree (0%) and
completely disagree (0%).
Speech
Statements #22: NPC patients should undergo a com-
prehensive communication evaluation by a speech and
language therapist and receive appropriate treatment.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (87%), mostly agree
(7%), partially agree (7%), mostly disagree (0%) and
completely disagree (0%).
Spasticity
Statements #23: Individuals with NPC may benefit from
assessments for spasticity and incipient or established
contracture. Spasticity and spasms should be treated at an
early stage, initially by non-pharmacological means. If these
are unsuccessful, pharmacological agents including Baclo-
fen, Tizanidine, Benzodiazepines, Dantrolene sodium and
botulinum toxin injections may be considered.
 Strength of recommendation: 1
 Level of evidence: B
Table 6 Recommended assessments
Recommended assessment Rationale Frequency References
Baseline history Establish current level of disease severity and
retrospectively estimate rate of progression
At diagnosis [9, 62, 78]
Interval history Establish rate of disease progression; monitor for
compliance with and side effects from therapy;
monitor for conditions which would prompt
discontinuation of therapy
6 months [62, 78]
Physical examination Document growth parameters, assess for
neurological features and organomegaly
At diagnosis then every 6–12 months [61, 62]
NPC clinical severity score Document key features of disease at diagnosis,
progression and response to therapy
At diagnosis and then every 6 months [22, 24, 32, 61]
Neuropsychiatric evaluation Document and treat psychiatric manifestations
and response to therapy
At diagnosis then every 6–12 months [62, 79]
Developmental or cognitive
assessment
Document baseline degree of cognitive
impairment and monitor response to therapy
At diagnosis; every 6 months in children;
every 12 months in adults
[9, 47, 61, 80]
Ophthalmology evaluation Document saccadic eye movement velocity and
presence of gaze palsy at baseline and document
response to miglustat therapy in treated patients
At diagnosis; at 6 and 12 months; after starting
treatment; frequency after 12 months can be
determined by clinical response
[61]
Audiometry Document presence of hearing loss At diagnosis then every 12 months [81]
Swallowing assessment Clinical swallowing assessment in all patients;
videofluoroscopic swallowing (VFS) assessment
may be useful in some patients; Document
presence of dysphagia and aspiration and
response to therapy
At diagnosis and then every 6 months in children;
in adults, frequency could be reduced to every
12 months if asymptomatic and disease is stable
[61, 82]
Neuroimaging Magnetic resonance imaging or more detailed
forms of neuroimaging including MR
spectroscopy and diffusion tensor imaging
At baseline if available; Decisions about follow
up neuroimaging will depend on local availability
and need for general anaesthesia
[47, 83–85]
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 Experts opinion: completely agree (93%), mostly agree
(7%), partially agree (0%), mostly disagree (0%) and
completely disagree (0%).
Bowel dysfunction
Statements #24: Consider modifying diet and lifestyle to
optimize stool consistency and avoid faecal impaction
and incontinence. If required, consider appropriate laxa-
tives to optimize gut transit and stool consistency.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (80%), mostly agree
(20%), partially agree (0%), mostly disagree (0%) and
completely disagree (0%).
Bladder dysfunction
Statements #25: Individuals with NPC should have their
history reviewed for symptoms suggestive of neurogenic
bladder (recurrent urinary tract infection, nocturia, in-
complete evacuation, dribbling) and be referred for uro-
logic evaluation if symptoms are present.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (79%), mostly agree
(21%), partially agree (0%), mostly disagree (0%) and
completely disagree (0%).
Cataplexy and seizures
Statements #26: Cataplexy and seizures are common
manifestations of NPC and their early recognition is im-
portant and should be managed promptly as per local/
national management guidelines. Protriptyline, other
tricyclic agents or modafanil have been efficacious for
cataplexy. Epilepsy should be treated by a neurologist
aware of the disease (possibility of aggravation with anti-
epileptic drugs like carbamazepine and vigabatrin should
be considered).
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (62%), mostly agree
(38%), partially agree (0%), mostly disagree (0%) and
completely disagree (0%).
Cognitive decline
Statements #27: Individuals with NPC benefit from
regular evaluation of their cognitive function and consider-
ation should be given to changes in their cognitive ability
that may impact on independence/school/work and daily
living activities. Testing should be age and functionally ap-
propriate, using standardised assessment tools. Strategies
to ensure the safety of the patient’s environment and the
availability of support mechanisms are essential to im-
prove the quality of life of the patient.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (80%), mostly agree
(13%), partially agree (7%), mostly disagree (0%) and
completely disagree (0%).
Mental wellbeing
Statements #28: Clinicians, caregivers and individuals
with NPC should be aware that there is an increased
prevalence of behavioural problems and other psychiatric
disorders such as anxiety, depression or psychosis in
NPC. There should be a low threshold for referral to a
clinical psychology/psychiatric team as appropriate, and
for the use of both non-pharmacological and/or pharma-
cological treatments.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (93%), mostly agree
(7%), partially agree (0%), mostly disagree (0%) and
completely disagree (0%).
Hypersalivation / drooling
Statements #29: Individuals with NPC are at increased
risk of hypersalivation/drooling and should be treated
with established interventions including postural drain-
age +/−pharmacological agents such as Hyoscine hydro-
bromide transdermal patches; Glycopyrronium orally,
subcutaneously or via a gastrostomy and small doses of
orally administered atropine, or parotid/submandibular
glandular injections of botulinum toxin.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (73%), mostly agree
(27%), partially agree (0%), mostly disagree (0%) and
completely disagree (0%).
Hearing
Statements #30: Individuals with NPC should undergo a
comprehensive hearing assessment at the time of diagno-
sis and thereafter annually. When appropriate, patients
should be offered hearing devices to improve general
communication.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (67%), mostly agree
(20%), partially agree (13%), mostly disagree (0%)
and completely disagree (0%).
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Disease modifying therapy
Miglustat
Miglustat, a substrate reduction therapy, is the only
licensed disease modifying medicine in the European
Union for the treatment of neurological manifesta-
tions of patients with NPC disease. In some patients,
miglustat has been shown to halt or attenuate disease
progression [60, 61].
Miglustat start criteria Statement # 31: All patients
with a confirmed diagnosis of NPC should be considered
for miglustat therapy
 Strength of recommendation: 2
 Level of evidence: C
 Experts opinion: completely agree (13%), mostly agree
(38%), partially agree (13%), mostly disagree (25%)
and completely disagree (13%).
To understand the effects of disease modifying therapy
in NPC, information about the natural history of disease
progression is required. In one natural history of NPC, a
cohort of 57 NPC patients was analysed, with 85.7% who
were followed up for more than 1 year showed neuro-
logical disease progression [62]. In this cohort were chil-
dren < 6 years who had normal evaluation suggesting
they might have had a late onset phenotype. The rate of
progression was 0.12 points per year (CI 0.09 to 0.15)
using a composite NPC scoring system where the max-
imum score of 4 indicates severe disease. The rates of
progression correlated with age at diagnosis, the younger
patients showing the greatest progression of disease.
A phase I/II study of miglustat was performed in 29
patients ≥12 years of age with proven NPC [61] Patients
were randomised 2:1 to receive miglustat 200 mg tds or
standard care for 1 year, with the option for adult pa-
tients to enrol into a further 1 year extension study to
receive active drug. A further subgroup of 12 patients
≤12 years received miglustat at a dose based on body
surface area. The study included male and female patients
with NPC confirmed by cholesterol esterification and ab-
normal filipin staining, able to safely ingest a capsule, with
normal renal function and not suffering from clinically
significant diarrhoea. Patients with other medical condi-
tions or were on concomitant medications that would ren-
der them unsuitable for the study were excluded. Patients
were assessed for the primary end point – change in hori-
zontal saccadic eye movements (HSEM) at baseline and at
12 months. At each assessment of eye movement velocity
was tested twice during a 24 h period. Swallowing ability
was assessed at screening, 6 months and 12 months.
Neurological assessments and quality of life assessments
were performed at screening, 3, 6, 9 and 12 months.
Treatment with Miglustat resulted in improvements in
the primary end point (HSEM) compared with standard
care. At 12 months, HSEM velocity had improved in pa-
tients treated with miglustat versus those receiving standard
care; results were significant when patients taking benzodi-
azepines were excluded (p = 0.028). Children showed an
improvement in HSEM velocity of similar magnitude at
12 months. Improvement in swallowing capacity, stable
auditory acuity, and a slower deterioration in ambulatory
index were also seen in treated patients older than 12 years.
Safety assessments were performed at screening every 3
months and at post screening follow up. Adverse events
(AEs) were recorded at each post-screening visit. The most
frequently occurring AEs were diarrhoea (85%), flatulence
(70%), and weight loss (65%). Discontinuation was reported
in one paediatric patient due to memory impairment and
in one adult patient due to confusional state and in one
other adult patient due to diarrhoea. No deaths were re-
ported. The study concluded that Miglustat was safe and
improved or stabilised several clinically relevant markers of
NPC [61]. This is the first agent studied in NPC for which
there is both animal and clinical data supporting a disease
modifying benefit.
Longer term (24 month) data of patients in the above
study, as part of an open label extension has been reported
[63]. 19/29 patients from the pivotal study completed the
two-year study of whom 15/19 completed 24 months of
miglustat therapy. The 24-month data did not meet the
primary end point of improvement in HSEM velocity.
Small patient numbers produced wide confidence intervals
making the data unreliable; however a modest deterior-
ation in HSEM velocity was noted. Overall there was sta-
bilisation of neurological symptoms (cognition, ambulation
and swallow) in 68% of this group with a trend towards im-
provement when compared to the natural history data.
Statement #32: NPC patients who are pre-symptomatic
or have only spleen/liver enlargement should not be offered
miglustat.
 Strength of recommendation 2
 Level of evidence C
 Experts opinion: completely agree (27%), mostly
agree (40%), partially agree (27%), mostly disagree
(7%) and completely disagree (0%).
All pre-symptomatic subjects should undergo regular
evaluation by a neurologist and/or metabolic physician,
so that treatment can be considered at an early onset of
neurological manifestation.
Statement #33: Miglustat should not be started in NPC
patients with advanced neurological disease/dementia.
 Strength of recommendation 2
 Level of evidence C
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 Experts opinion: completely agree (47%), mostly agree
(33%), partially agree (20%), mostly disagree (0%)
and completely disagree (0%).
Currently there are limited data on patients with NPC
with advanced neurological disease being commenced
on miglustat. Based on the French experience of miglu-
stat treatment in 20 children the NPC disability scores
improved or stabilized in 75% of the patients with late-
infantile onset disease (onset of symptoms < 5 years of
age) but no patients with the early infantile onset form
(onset of symptoms < 1 year of age) had a good neuro-
logical outcome [64]. Only one patient out of 9 children
treated before 4 years of age demonstrated stabilisation.
More data are needed to determine of the efficacy of
miglustat in patients below the age of 4 years.
Miglustat therapy is NOT appropriate for patients who
have profound neurological disease, which, in the opin-
ion of the attending physician, would make it difficult to
assess for any improvements with therapy. Such symp-
toms may include but are not limited to:
a. Profound dementia resulting in the need for 24 h care
b. Inability to ambulate without a wheelchair
c. Complete lack of verbal communication
d. Swallowing difficulties profound enough to require
tube feeding through a per-cutaneous gastrostomy
Statement #34: Miglustat should not be started in
NPC patients with another life threatening illness with
estimated life span less than 1 year.
 Strength of recommendation 2
 Level of evidence C
 Experts opinion: completely agree (73%), mostly agree
(20%), partially agree (7%), mostly disagree (0%) and
completely disagree (0%).
Whilst there is no evidence in the literature to
assess this, most guidelines for other new therapies
such as enzyme replacement therapies, and some
national guidelines specify the above as an exclusion
criteria [65, 66].
Experimental therapies
Clinical trials testing the safety and efficacy of intrathecal
[67] or intravenous preparations of 2-hydroxypropyl- β-
cyclodextrin and oral Arimoclomol are ongoing. Al-
though the disease is a disorder of cholesterol traffick-
ing, cholesterol-lowering drugs have not been shown to
be effective at altering the course of the disease [68, 69].
In addition, a number of other therapeutic modalities in
animal and early phase human studies are underway.
Follow up, transition, advanced care planning and genetic
issues
Follow up
Statements #35: NPC is a progressive condition and
patients require regular follow up. Treatment goals should
be established at diagnosis and reviewed regularly, aimed
at improving or maintaining the physical and psychosocial
wellbeing of individuals with NPC and their families.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (88%), mostly agree
(6%), partially agree (6%), mostly disagree (0%) and
completely disagree (0%).
Transition
Statements #36: Most children with late-infantile and
juvenile onset NPC are expected to reach adulthood with
complex medical and psychosocial needs. The process of
transition from paediatric to adult services should begin
early and must include appropriate services in the com-
munity to provide a seamless transition from childhood to
adult life. Individuals with NPC may benefit from a de-
tailed assessment identifying barriers to independence.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (88%), mostly
agree (13%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%).
Advance care planning
Statements #37: Specialist centre care providers, family
physician/paediatrician and local palliative care services
should develop close working links to support individuals
and families with NPC through the lifespan, including: a)
advance care planning with regular updating. b) proper
flow of communication and information for patients and
their families, c) a designated point of contact for each
stage in their care pathway. An individual identified as
being near the end- of-life may benefit from ongoing access
to palliative care services including for symptom control,
respite, psychological and spiritual support.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (94%), mostly agree
(6%), partially agree (0%), mostly disagree (0%) and
completely disagree (0%).
Genetic issues
Statements #38: Requests for NPC pre-symptomatic gen-
etic testing are best managed on a case-by-case basis.
Pre-symptomatic testing in minors is not permitted in
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some jurisdictions, and in any case, the risks and benefits
from the perspectives of both the child and parents
should be carefully discussed in the context of formal
counselling from a suitably qualified individual. All pa-
tients identified pre-symptomatically should be referred to
specialist centres for surveillance and early detection of
neurological manifestations.
 Strength of recommendation: 2
 Level of evidence: B
 Experts opinion: completely agree (81%), mostly agree
(6%), partially agree (13%), mostly disagree (0%) and
completely disagree (0%).
Statements #39: Prenatal testing for NPC should be
offered to all at risk couples and requires careful counsel-
ling by clinical geneticists and NPC specialists. Molecular
genetic analysis of chorionic villus samples is the strategy
of choice, based on mutations identified in the family.
 Strength of recommendation: 1
 Level of evidence: B
 Experts opinion: completely agree (75%), mostly agree
(13%), partially agree (6%), mostly disagree (6%) and
completely disagree (0%).
Conclusion
These guidelines are the result of an international col-
laboration of experts in the care of NPC and the evi-
dence gathered to write these guidelines is the best
evidence available to the experts. These guidelines ad-
dress the management of children and adults affected by
NPC and are intended to facilitate optimal care to all
NPC patients regardless of their demography and access
to health care. In addition, it defines standard of care
against which practice can be audited and best practice
can be spread. The Guidelines Working Group commits
itself to revise this work in 5 years’ time to reflect new
data pertaining to future research findings and new
therapies.
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